The Sentinel cerebral protection system (Boston Scientific) was infrequently used during TAVI procedures performed in Germany over a recent 3-year span, and it was not associated with less clinical ...

Debris from the proximal filter of the Sentinel system, including valve tissue, arterial wall with acute thrombus, calcification, and myocardium (Photo Credit: Aloke Finn) In a small, prospective ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter aortic valve replacement (TAVR), the investigational Emboliner device ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...

A redesigned embolic protection device failed to protect transcatheter aortic valve replacement (TAVR) patients against stroke, the REFLECT II study showed. Efficacy outcomes were no better ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection ...